Latest & greatest articles for atenolol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atenolol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atenolol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atenolol

1. Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome

Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome 30261963 2018 09 28 1558-3597 72 14 2018 Oct 02 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome. 1613-1618 S0735-1097(18)35818-2 10.1016/j.jacc.2018.07.052 Beta-blockers are the standard treatment in Marfan syndrome (MFS). Recent clinical trials with limited follow-up yielded conflicting (...) results on losartan's effectiveness in MFS. The present study aimed to evaluate the benefit of losartan compared with atenolol for the prevention of aortic dilation and complications in Marfan patients over a longer observation period (>5 years). A total of 128 patients included in the previous LOAT (LOsartan vs ATenolol) clinical trial (64 in the atenolol and 64 in the losartan group) were followed up for an open-label extension of the study, with the initial treatment maintained. Mean clinical

EvidenceUpdates2018

2. Atenolol

Atenolol Top results for atenolol - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for atenolol The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

3. Atenolol versus losartan in children and young adults with Marfan's syndrome.

Atenolol versus losartan in children and young adults with Marfan's syndrome. BACKGROUND: Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers. METHODS: We conducted a randomized trial comparing losartan with atenolol in children and young adults with Marfan's syndrome. The primary outcome was the rate (...) centers enrolled 608 participants, 6 months to 25 years of age (mean [±SD] age, 11.5±6.5 years in the atenolol group and 11.0±6.2 years in the losartan group), who had an aortic-root z score greater than 3.0. The baseline-adjusted rate of change in the mean (±SE) aortic-root z score did not differ significantly between the atenolol group and the losartan group (-0.139±0.013 and -0.107±0.013 standard-deviation units per year, respectively; P=0.08). Both slopes were significantly less than zero

NEJM2014 Full Text: Link to full Text with Trip Pro

4. Atenolol

Atenolol USE OF ATENOLOL IN PREGNANCY 0344 892 0909 USE OF ATENOLOL IN PREGNANCY (Date of issue: March 2016 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Atenolol is a cardioselective (beta1 selective) beta-adrenoceptor blocking (...) drug (beta-blocker) licensed for the treatment of hypertension, angina pectoris, cardiac dysrhythmia, and for early intervention in the acute phase of myocardial infarction. Data on overall rates of fetal structural malformations, or of specific malformations following first trimester use of atenolol, are too limited to permit an evidence-based risk assessment. There are also insufficient data to assess the risk of spontaneous abortion, stillbirth and adverse neurodevelopmental outcomes following

UK Teratology Information Service2014

5. Atenolol compared with nifedipine: effect on cognitive function and mood in elderly hypertensive patients.

Atenolol compared with nifedipine: effect on cognitive function and mood in elderly hypertensive patients. Atenolol compared with nifedipine... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1992 ) Volume: 116 , Issue: 8 , Pages: 615-623 PubMed: Available from or Find this paper at: Abstract OBJECTIVE: To compare the effects of atenolol and nifedipine on mood and cognitive function (...) in elderly hypertensive patients. DESIGN: Randomized, double-blind, crossover trial. PATIENTS: Thirty-one elderly volunteers (7 women and 4 men) 60 to 81 years of age with mild to moderate hypertension were recruited from the general community and a Veterans Affairs hospital hypertension clinic. Six volunteers withdrew at early phases of the study for reasons unrelated to adverse drug effects. INTERVENTIONS: Participants had 2 weeks of placebo, to 6 weeks of titration with atenolol or nifedipine

Annals of Internal Medicine2013

6. Effect of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients

Effect of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients 23086971 2012 12 03 2013 01 29 2014 11 20 1468-201X 98 24 2012 Dec Heart (British Cardiac Society) Heart Differential effects of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients. 1812-6 10.1136/heartjnl-2012-302795 To assess whether reduction of heart rate (HR) has beneficial effects on endothelial function (...) in patients with type 2 diabetes mellitus (T2DM). Randomised, double-blind, placebo-controlled study. University hospital. 66 T2DM patients without overt cardiovascular disease. Patients were randomised to receive for 4 weeks, in addition to their standard therapy, one of the following treatments: atenolol (25 mg twice daily), ivabradine (5 mg twice daily) or placebo (1 tablet twice daily). Systemic endothelial function, assessed by flow-mediated dilation (FMD); endothelium-independent vasodilation

EvidenceUpdates2012

7. The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT

The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared (...) with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlof B, Sever PS, Wedel H, Jonsson B, Anglo-Scandinavian Cardiac Outcomes Trial investigators Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment

NHS Economic Evaluation Database.2009

8. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen

Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen 17916665 2008 01 15 2008 01 30 2013 11 21 1468-201X 94 2 2008 Feb Heart (British Cardiac Society) Heart Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. e4 To compare the cost effectiveness of an amlodipine-based strategy and an atenolol (...) -based strategy in the treatment of hypertension in the UK and Sweden. A prospective, randomised trial complemented with a Markov model to assess long-term costs and health effects. Primary care. Patients with moderate hypertension and three or more additional risk factors. Amlodipine 5-10 mg with perindopril 4-8 mg added as needed or atenolol 50-100 mg with bendroflumethiazide 1.25-2.5 mg and potassium added as needed Cost per cardiovascular event and procedure avoided, and cost per quality-adjusted

EvidenceUpdates2008

9. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen

Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen Lindgren P, Buxton M, Kahan T, Poulter N (...) R, Dahlof B, Sever P S, Wedel H, Jonsson B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to compare the cost-effectiveness of an amlodipine-based strategy and an atenolol-based strategy in the treatment

NHS Economic Evaluation Database.2008

10. Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension

Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension Article Text Therapeutics Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications

Evidence-Based Medicine (Requires free registration)2007

11. Review: atenolol may be ineffective for reducing cardiovascular morbidity or all cause mortality in hypertension

Review: atenolol may be ineffective for reducing cardiovascular morbidity or all cause mortality in hypertension Review: atenolol may be ineffective for reducing cardiovascular morbidity or all cause mortality in hypertension | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: atenolol may be ineffective for reducing cardiovascular morbidity or all cause mortality in hypertension Article Text Therapeutics Review: atenolol may be ineffective for reducing cardiovascular morbidity or all cause mortality in hypertension Free J Kennedy Cruickshank , MD

Evidence-Based Medicine (Requires free registration)2006

12. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-B

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-B 16154016 2005 09 12 2005 10 12 2015 06 16 1474-547X 366 9489 2005 Sep 10-16 Lancet (London, England) Lancet Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol (...) , therefore, was to compare the effect on non-fatal myocardial infarction and fatal CHD of combinations of atenolol with a thiazide versus amlodipine with perindopril. We did a multicentre, prospective, randomised controlled trial in 19 257 patients with hypertension who were aged 40-79 years and had at least three other cardiovascular risk factors. Patients were assigned either amlodipine 5-10 mg adding perindopril 4-8 mg as required (amlodipine-based regimen; n=9639) or atenolol 50-100 mg adding

Lancet2005

13. Atenolol in hypertension: is it a wise choice?

Atenolol in hypertension: is it a wise choice? Atenolol in hypertension: is it a wise choice? Atenolol in hypertension: is it a wise choice? Carlberg B, Samuelsson O, Lindholm L H CRD summary This review assessed the effect of atenolol on cardiovascular morbidity and mortality in patients with hypertension. The authors concluded that atenolol may not be a suitable treatment option for patients with hypertension, and queried its use as a reference drug in trials. Limitations in the reporting (...) of the review process and the lack of a validity assessment weaken this conclusion. Authors' objectives To assess the effect of atenolol on cardiovascular morbidity or mortality in patients with primary hypertension. Searching The Cochrane Library, MEDLINE and relevant textbooks were searched to identify studies; the database search terms were given. Researchers in the field of hypertension were also contacted. Study selection Study designs of evaluations included in the review Randomised controlled trials

DARE.2004

14. Cost-effectiveness of losartan versus atenolol in treating hypertension: an analysis of the LIFE study from a Swiss perspective

Cost-effectiveness of losartan versus atenolol in treating hypertension: an analysis of the LIFE study from a Swiss perspective Cost-effectiveness of losartan versus atenolol in treating hypertension: an analysis of the LIFE study from a Swiss perspective Cost-effectiveness of losartan versus atenolol in treating hypertension: an analysis of the LIFE study from a Swiss perspective Szucs T D, Burnier M, Erne P Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the use of an angiotensin II receptor blocker (losartan) with the use of a beta-blocker (atenolol) in patients with essential hypertension. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study

NHS Economic Evaluation Database.2004

15. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.

Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. 14734593 2004 01 21 2004 01 29 2016 10 17 1538-3598 291 3 2004 Jan 21 JAMA JAMA Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. 309-16 Many patients with chronic angina experience anginal (...) have symptoms of chronic angina and who experience angina and ischemia at low workloads despite taking standard doses of atenolol, amlodipine, or diltiazem and to determine times to angina onset and to electrocardiographic evidence of myocardial ischemia, effect on angina attacks and nitroglycerin use, and effect on long-term survival in an open-label observational study extension. A randomized, 3-group parallel, double-blind, placebo-controlled trial of 823 eligible adults with symptomatic chronic

JAMA2004

16. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. 11937178 2002 04 08 2002 04 24 2015 06 16 0140-6736 359 9311 2002 Mar 23 Lancet (London, England) Lancet Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. 995-1003 Blood pressure reduction achieved with beta-blockers and diuretics (...) with essential hypertension (sitting blood pressure 160-200/95-115 mm Hg) and LVH ascertained by electrocardiography (ECG). We assigned participants once daily losartan-based or atenolol-based antihypertensive treatment for at least 4 years and until 1040 patients had a primary cardiovascular event (death, myocardial infarction, or stroke). We used Cox regression analysis to compare regimens. Blood pressure fell by 30.2/16.6 (SD 18.5/10.1) and 29.1/16.8 mm Hg (19.2/10.1) in the losartan and atenolol groups

Lancet2002

17. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. 11937179 2002 04 08 2002 04 24 2015 06 16 0140-6736 359 9311 2002 Mar 23 Lancet (London, England) Lancet Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. 1004-10 The most suitable (...) antihypertensive drug to reduce the risk of cardiovascular disease in patients with hypertension and diabetes is unclear. In prespecified analyses, we compared the effects of losartan and atenolol on cardiovascular morbidity and mortality in diabetic patients. As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based

Lancet2002

18. An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 54)

An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 54) An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 54) An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 54) Gray A, Clarke P, Raikou M, Adler A, Stevens R, Neil A, Cull C, Stratton I, Holman R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health interventions under study were two antihypertensive therapies, atenolol (a beta-blocker, daily dose of 50 mg, increasing to 100 mg if required) and captopril (an angiotensin converting enzyme inhibitor (ACE), 25 mg twice daily increasing to 50 mg twice daily), in patients with type-2 diabetes. Type

NHS Economic Evaluation Database.2001

19. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.

Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. 9732338 1998 10 28 1998 10 28 2014 06 17 0959-8138 317 7160 1998 Sep 12 BMJ (Clinical research ed.) BMJ Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. 713-20 To determine whether tight control of blood (...) pressure with either a beta blocker or an angiotensin converting enzyme inhibitor has a specific advantage or disadvantage in preventing the macrovascular and microvascular complications of type 2 diabetes. Randomised controlled trial comparing an angiotensin converting enzyme inhibitor (captopril) with a beta blocker (atenolol) in patients with type 2 diabetes aiming at a blood pressure of <150/<85 mm Hg. 20 hospital based clinics in England, Scotland, and Northern Ireland. 1148 hypertensive patients with

BMJ1998 Full Text: Link to full Text with Trip Pro

20. A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients

A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients (...) initiation to termination of treatment in primary studies) in SBP and in the ratio TC:HDL-C, and the utilities attributed to health states. Study designs and other criteria for inclusion in the review Randomised controlled trials were included. The studies were selected if they included either atenolol or celiprolol. Sources searched to identify primary studies Not reported (the reader was referred to a previously published meta-analysis). Criteria used to ensure the validity of primary studies

NHS Economic Evaluation Database.1997